Policy & Regulation
NFL Biosciences enrolls first participant in Phase 2 smoking cessation trial
19 November 2026 -

French biopharmaceutical company NFL Biosciences (Euronext Growth Paris:ALNFL) said on Thursday that it has enrolled the first participant in its Phase 2 TONIC clinical study evaluating NFL-102 for smoking and nicotine cessation, marking the start of the trial's clinical phase.

The first participant was enrolled at the Eurofins Optimed clinical centre in Gières, France.

The multicentre, randomised, double-blind, placebo-controlled study will involve 310 smokers across France and assess NFL-102, a drug candidate designed to enhance neuroplasticity and address addiction. Its primary endpoint is four weeks of continuous abstinence, verified through urinary cotinine measurements.

The first stage, Part A, will involve 40 participants and evaluate three initial doses. An independent data monitoring committee and the company will review unblinded safety and efficacy data to determine which dose should be discontinued.

Initial results from Part A are expected in April 2027. The study will then progress to Part B, targeting an additional 270 participants across approximately 10 clinical centres, with further dose selection following the enrolment of the first 150 participants.

Login
Username:

Password: